Ocular rebamipide takes development lead at Acucela
This article was originally published in Scrip
Executive Summary
Acucela and its partner Otsuka Pharmaceutical have begun a US Phase III trial with an ophthalmic suspension formulation of rebamipide for dry eye, making the project Acucela's most advanced commercial candidate.